title: Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21).
abstract: Acute myelogenous leukemia with t(8;21) is a distinct clinicopathologic entity in which the malignant myeloblasts display a characteristic pattern of surface antigen expression. Quantitative analysis of surface marker expression in patients with this chromosomal abnormality compared to acute myelogenous leukemia patients with a different karyotype has not been reported. From 305 consecutive newly diagnosed acute myelogenous leukemia patients underwent immunophenotyping and cytogenetic analysis at our center; 16 patients (5.2%) had a t(8;21). Fluorescence intensity values were obtained, using a set of reference microbeads, by conversion of mean channel fluorescence to molecular equivalent of soluble fluorochrome. Patients with t(8;21) displayed higher levels of CD34, HLA-DR and MPO expression (P < 0.001 for each) and lower levels of CD13 (P = 0.03) and CD33 (P = 0.02) expression. In order to study the sensitivity, specificity and predictive value of these markers, molecular equivalent of soluble fluorochrome thresholds were statistically determined. The statistically established threshold for each of the individual markers (CD34 > 60.5 x 10(3), HLA-DR > 176.1 x 10(3), MPO > 735.1 x 10(3), CD13 < 24.3 x 10(3) and CD33 < 17.3 x 10(3)) had a sensitivity of 100%, a specificity of 62-92% and a positive predictive value of 7-45%. In multivariate analysis, two quantitative patterns (CD34 > 60.5 x 10(3) and MPO > 176.1 x 10(3); CD33 < 17.3 x 10(3) and MPO > 176.1 x 10(3)) had a sensitivity, specificity and positive predictive value of 100%. These aberrant phenotypic patterns might help identify patients with t(8;21) at diagnosis and could be useful in minimal residual disease monitoring.
authors.affiliation: Department of Cellular and Molecular Biology, Princess Margaret Hospital, Toronto, Ontario, Canada. khaytham@uhnres.utoronto.ca
authors.forename: Haytham
authors.initials: H
authors.lastname: Khoury
authors.forename: Bakul I
authors.initials: BI
authors.lastname: Dalal
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Nantel
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Horsman
authors.forename: Julye C
authors.initials: JC
authors.lastname: Lavoie
authors.forename: John D
authors.initials: JD
authors.lastname: Shepherd
authors.forename: Donna E
authors.initials: DE
authors.lastname: Hogge
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Toze
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Song
authors.forename: Donna L
authors.initials: DL
authors.lastname: Forrest
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Sutherland
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Nevill
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D003937:Diagnosis, Differential; D005434:Flow Cytometry / Q000379:methods; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D011237:Predictive Value of Tests; D014178:Translocation, Genetic
chemical_list: D015703:Antigens, CD; D006684:HLA-DR Antigens